全文获取类型
收费全文 | 1021篇 |
免费 | 43篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 34篇 |
妇产科学 | 19篇 |
基础医学 | 141篇 |
口腔科学 | 10篇 |
临床医学 | 79篇 |
内科学 | 275篇 |
皮肤病学 | 24篇 |
神经病学 | 97篇 |
特种医学 | 22篇 |
外科学 | 70篇 |
综合类 | 4篇 |
预防医学 | 78篇 |
眼科学 | 10篇 |
药学 | 54篇 |
中国医学 | 1篇 |
肿瘤学 | 146篇 |
出版年
2024年 | 1篇 |
2023年 | 15篇 |
2022年 | 20篇 |
2021年 | 41篇 |
2020年 | 15篇 |
2019年 | 30篇 |
2018年 | 35篇 |
2017年 | 22篇 |
2016年 | 31篇 |
2015年 | 29篇 |
2014年 | 31篇 |
2013年 | 48篇 |
2012年 | 84篇 |
2011年 | 77篇 |
2010年 | 45篇 |
2009年 | 35篇 |
2008年 | 56篇 |
2007年 | 71篇 |
2006年 | 70篇 |
2005年 | 67篇 |
2004年 | 69篇 |
2003年 | 57篇 |
2002年 | 48篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 9篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 6篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1989年 | 5篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1978年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有1070条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
Fulvia Milena Cribi Roberta Erra Lorenza Pugni Carlota Rubio-Perez Lidia Alonso Sara Simonetti Giorgio Alberto Croci Garazi Serna Andrea Ronchi Carlo Pietrasanta Giovanna Lunghi Anna Maria Fagnani Maria Piana Matthias Matter Alexandar Tzankov Luigi Terracciano Andres Anton Enrico Ferrazzi Stefano Ferrero Enrico Iurlaro Joan Seoane Paolo Nuciforo 《The Journal of clinical investigation》2021,131(6)
15.
Ian J Majewski Lorenza Mittempergher Nadia M Davidson Astrid Bosma Stefan M Willems Hugo M Horlings Iris de Rink Liliana Greger Gerrit KJ Hooijer Dennis Peters Petra M Nederlof Ingrid Hofland Jeroen de Jong Jelle Wesseling Roelof JC Kluin Wim Brugman Ron Kerkhoven Frank Nieboer Paul Roepman Annegien Broeks Thomas R Muley Jacek Jassem Jacek Niklinski Nico van Zandwijk Alvis Brazma Alicia Oshlack Michel van den Heuvel René Bernards 《The Journal of pathology》2013,230(3):270-276
16.
Carla Sappino Ludovica Primitivo Martina De Angelis Francesco Righi Federica Di Pietro Marika Iannoni Luciano Pilloni Stefano Vecchio Ciprioti Lorenza Suber Alessandra Ricelli Giuliana Righi 《RSC advances》2020,10(50):29688
A linear β-amino alcohol ligand, previously found to be a very efficient catalyst for enantioselective addition of dialkylzinc to aromatic aldehydes, has been anchored on differently functionalized superparamagnetic core–shell magnetite–silica nanoparticles (1a and 1b). Its catalytic activity in the addition of dialkylzinc to aldehydes has been evaluated, leading to promising results, especially in the case of 1b for which the recovery by simple magnetic decantation and reuse was successfully verified.The catalytic activity of a linear β-amino alcohol ligand anchored on functionalized magnetite/silica core–shell nanoparticles has been evaluated in the addition of dialkylzinc to aldehydes leading to promising results. 相似文献
17.
Tanda ML Piantanida E Lai A Liparulo L Sassi L Bogazzi F Wiersinga WM Braverman LE Martino E Bartalena L 《Clinical endocrinology》2008,69(5):812-818
Objective To investigate how North American thyroidologists assess and treat amiodarone‐induced thyrotoxicosis (AIT) and to compare the results with those of the same questionnaire‐based survey previously carried out among European thyroidologists. Design Members of the American Thyroid Association (ATA) with clinical interests were sent by e‐mail a questionnaire on the diagnosis and management of AIT, 115 responses were received from the United States and Canada, representing about one‐third of ATA members with clinical interests. Results The majority of respondents (91%vs. 68% in Europe, P < 0·05) see < 10 new cases of AIT per year, and AIT seems less frequent than amiodarone‐induced hypothyroidism (AIH) in North America (34% and 66% of amiodarone‐induced thyroid dysfunction, respectively, vs. 75% and 25%, respectively, in Europe, P < 0·001). When AIT is suspected, in North America hormonal assessment is mostly based on serum free T4 (FT4) and TSH measurements, while serum free T3 (FT3) determination is requested less frequently than in Europe; thyroid autoimmunity is included in the initial assessment less than in Europe. Most commonly used additional diagnostic procedures include, as in Europe, thyroid colour‐flow Doppler sonography, and to a lesser extent, thyroid radioactive iodine uptake and scan, but Europeans tend to request multiple tests more than North Americans. Withdrawal of amiodarone is more often considered unnecessary by North American thyroidologists (21%vs. 10% in Europe in type 1 AIT, P < 0·05, 34%vs. 20% in type 2 AIT, P < 0·05). In type 1 AIT thionamides represent the treatment of choice for North Americans as well as for Europeans, but the former use them as monotherapy in 65%vs. 51% of Europeans (P < 0·05) who more often consider potassium perchlorate as an useful addition (31%vs. 15% of North Americans, P < 0·01). Glucocorticoids are the selected treatment for type 2 AIT, alone (62%vs. 46% in Europe, P < 0·05) or in association with thionamides (16%vs. 25% in Europe, P = NS). After restoration of euthyroidism, thyroid ablation in the absence of recurrent thyrotoxicosis is recommended in type 1 AIT less frequently by North Americans. If amiodarone therapy needs to be reinstituted, prophylactic thyroid ablation is advised by 76% in type 1 AIT, while a ‘wait‐and‐see’ strategy is adopted by 61% in type 2 AIT, similar to behaviour of European thyroidologists. Conclusion Similarities and differences exist between expert North American and European thyroidologists concerning the diagnosis and management of AIT. While differences reflect the frequent uncertainty of the underlying mechanism leading to AIT, similarities may represent the basis to refine the diagnostic criteria and to improve the therapeutic outcomes of this challenging clinical situation. 相似文献
18.
Giordano R Picu A Broglio F Bonelli L Baldi M Berardelli R Ghigo E Arvat E 《Pituitary》2004,7(4):243-248
Ghrelin, a peptide predominantly produced by the stomach, has been discovered as a natural ligand of the GH Secretagogue receptor
type 1a (GHS-R1a), known as specific for synthetic GHS. Ghrelin has recently attracted considerable interest as a new orexigenic
factor. However, ghrelin exerts pleiotropic actions that are explained by the widespread distribution of ghrelin and GHS-R
expression. Besides strong stimulation of GH secretion, the neuroendocrine ghrelin actions also include significant stimulation
of both lactotroph and corticotroph secretion; all these actions depend on acylation of ghrelin in serine-3 that allows binding
and activation of the GHS-R1a. However, GHS-R subtypes are likely to exist; they also bind unacylated ghrelin that is, in
fact, the most abundant circulating form and exerts some biological actions. Ghrelin secretion is mainly regulated by metabolic
signals, namely inhibited by feeding, glucose and insulin while stimulated by energy restriction. The role of glucocorticoids
on ghrelin synthesis and secretion is still unclear although morning ghrelin levels have been found reduced in some patients
with Cushing's syndrome; this, however, would simply reflect its negative association to body mass. Ghrelin, like synthetic
GHS, stimulates ACTH and cortisol secretion in normal subjects and this effect is generally sensitive to the negative glucocorticoid
feedback. It is remarkable that, despite hypercortisolism, ghrelin as well as synthetic GHS display marked increase in their
stimulatory effect on ACTH and cortisol secretion in patients with Cushing's disease. This is even more intriguing considering
that the GH response to ghrelin and GHS is markedly reduced by glucocorticoid excess. It has been demonstrated that the ACTH-releasing
effect of ghrelin and GHS is purely mediated at the central level in physiological conditions; its enhancement in the presence
of ACTH-secreting tumours is, instead, likely to reflect direct action on GHS receptors present on the neoplastic tissues.
In fact, peculiar ACTH hyperresponsiveness to ghrelin and GHS has been observed also in ectopic ACTH-secreting tumours. 相似文献
19.
Morales A Morimoto S Díaz L Robles G Díaz-Sánchez V 《The Journal of endocrinology》2008,197(2):309-314
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an endothelial cell mitogen, expressed essentially in steroidogenic cells. Recently, the expression of EG-VEGF in normal human pancreas and pancreatic adenocarcinoma has been demonstrated. Epidemiologically, pancreatic carcinogenesis is more frequent in males than females, and given that androgen receptors and testosterone biotransformation have been described in pancreas, we hypothesized that testosterone could participate in the regulation of EG-VEGF expression. In this study, we investigated the regulation of EG-VEGF gene expression by testosterone in normal rat pancreatic tissue and rat insulinoma cells (RINm5F). Total RNA was extracted from rat pancreas and cultured cells. Gene expression was studied by real-time PCR and protein detection by immunohistochemistry. Serum testosterone was quantified by RIA. Results showed that EG-VEGF is expressed predominantly in pancreatic islets and vascular endothelium, as well as in RINm5F cells. EG-VEGF gene expression was lower in the pancreas of rats with higher testosterone serum levels. A similar effect that was reverted by flutamide was observed in testosterone-treated RINm5F cells. In summary, testosterone down-regulated EG-VEGF gene expression in rat pancreatic tissue and RINm5F cells. This effect could be mediated by the androgen receptor. To our knowledge, this is the first time that a direct effect of testosterone on EG-VEGF gene expression in rat pancreas and RINm5F cells is demonstrated. 相似文献
20.